Arbor Pharmaceuticals, Inc.
Products
Focused Approach to Product Development & Commercialization
Arbor Pharmaceuticals utilizes a unique approach to product development and commercialization based on meeting the specific pharmaceutical needs of pediatricians. The company and its partners have experience across all areas of product development and commercialization.
Our focus is on late-stage product development that leads to efficient and timely introductions of novel and needed products. Additionally, all products introduced by Arbor incorporate novel child-centric features to improve the clinical benefits of the product. This approach will yield a robust pipeline of products that are well-suited for the pediatric market. Arbor’s first product, ZINOTIC®, is a unique otic product indicated to treat Acute Otitis Externa (AOE) and was introduced in August, 2007. Visit www.ZINOTIC.com to learn more about this important new treatment. Arbor’s second product, NEOTIC™, is a unique otic analgesic agent indicated to treat the pain and inflammation associated with Acute Otitis Media (AOM) and was introduced in October, 2008. Visit www.NEOTIC-RX.com to learn more about NEOTIC™.
The therapeutic focus of Arbor is closely aligned with the most common childhood illnesses. Specifically, the company’s initial commercialization and product development efforts are directed toward otic (ear) conditions and has also identified product candidates for other common pediatric illnesses. Arbor actively pursues product development opportunities through in-licensing and other collaborations. Please contact Arbor Pharmaceuticals to discuss product development opportunities that fit with the company’s pediatric focus.
Arbor commercializes its products in partnership with established pharmaceutical companies. Please contact Arbor Pharmaceuticals if you are interested in discussing a unique pediatric promotional opportunity.
